Merck & Company Inc (MRK)vsSophia Genetics SA (SOPH)
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
SOPH
Sophia Genetics SA
$5.28
+5.60%
HEALTHCARE · Cap: $358.34M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 84034% more annual revenue ($65.01B vs $77.27M). MRK leads profitability with a 28.1% profit margin vs -102.2%. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
SOPH
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Margin of Safety
-3.2%
Fair Value
$4.63
Current Price
$5.28
$0.65 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Revenue surging 22.4% year-over-year
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : SOPH
The strongest argument for SOPH centers on Revenue Growth. Revenue growth of 22.4% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : SOPH
The primary concerns for SOPH are EPS Growth, Market Cap, Debt/Equity.
Key Dynamics to Monitor
MRK profiles as a value stock while SOPH is a growth play — different risk/reward profiles.
SOPH carries more volatility with a beta of 1.04 — expect wider price swings.
SOPH is growing revenue faster at 22.4% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 26/100), backed by strong 28.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Sophia Genetics SA
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Sophia Genetics SA (SOPH) is a trailblazer in data-driven medicine, specializing in advanced genomic and clinical data analytics aimed at improving patient outcomes. Leveraging state-of-the-art machine learning algorithms, the company offers a robust platform that empowers hospitals and laboratories to decode complex genomic information, thereby enabling personalized treatment approaches, particularly in oncology, rare diseases, and hereditary conditions. With a strong global presence and strategic alliances with leading healthcare institutions, Sophia Genetics is dedicated to revolutionizing healthcare through precision medicine, reinforcing its status as a key player in the genomics sector.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?